Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Otolaryngeal Cancer 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Has results × Electroencephalography × Clear all
NCT03040024 2021-07-08

Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients

Emory University

Phase 4 Terminated
71 enrolled 17 charts
Head & Neck

Otolaryngeal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡